Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 9/20 | 0.43 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 2/20 | 0.35 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065656 | 0.97 | FLT1 (0.45) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL4071195 | 0.97 | FLT1 (0.46) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL3930923 | 0.92 | NPC1 (0.42) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL4069302 | 0.92 | NPC1 (0.44) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL4068409 | 0.90 | TYK2 (0.53) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL3936128 | 0.90 | NPC1 (0.43) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL3937751 | 0.90 | NPC1 (0.46) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL4073363 | 0.90 | NPC1 (0.43) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL4067376 | 0.90 | FLT1 (0.48) | FLT1EGFRKDRNPC1RAB9A | |
| SCHEMBL3938262 | 0.90 | IKBKB (0.42) | FLT1EGFRKDRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| WO-2009007421-A1 | INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | claimed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009007421-A1 | INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | FLT1 3775/4885EGFR 498/4885KDR 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.